SUD Reprocessing, Tissue Regulation Addressed By Australia’s TGA
This article was originally published in The Gray Sheet
Executive Summary
Device manufacturers will have a two-year phase-in period to comply with new 1single-use device reprocessing regulatory requirements proposed by Australia's Therapeutic Goods Administration
You may also be interested in...
Certain Aussie Home-Use IVDs Subject To Full Safety Evaluation – TGA
Sponsors of home-use in vitro diagnostics intended for the identification or monitoring of serious conditions will need to demonstrate that lay users are able to obtain comparable results to trained professionals, according to recently-released draft guidelines issued by Australia's Therapeutics Goods Administration
Australian Tissue Regs On Horizon; TGA Seeks Public Comments, Suggestions
Australia's Therapeutic Goods Administration (TGA) is soliciting comments on whether non-viable tissues should be incorporated into the country's upcoming system for regulating cell and tissue products or continue to be regulated as medical devices
Australian Medical Device Framework Takes Effect; Reuse Is On Horizon
Sponsors of the 20% of CE-marked Class I, Class IIa and Class IIb devices randomly selected to undergo an audit by Australia's Therapeutic Goods Administration will pay additional fees under the country's new medical device framework, which took effect Oct. 4